Ameriprise’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.4K | Sell |
10,391
-605
| -6% | -$831 | ﹤0.01% | 4036 |
|
|
2025
Q4 | $17.7K | Buy |
10,996
+420
| +4% | +$879 | ﹤0.01% | 4063 |
|
|
2025
Q3 | $28.9K | Sell |
10,576
-166,372
| -94% | -$553K | ﹤0.01% | 4031 |
|
|
2025
Q2 | $644K | Buy |
176,948
+164,896
| +1,368% | +$453K | ﹤0.01% | 3438 |
|
|
2025
Q1 | $23.1K | Buy |
12,052
+86
| +0.7% | +$176 | ﹤0.01% | 3975 |
|
|
2024
Q4 | $22.7K | Buy |
+11,966
| New | +$20.8K | ﹤0.01% | 4042 |
|
|
2023
Q1 | – | Sell |
-163,400
| Closed | -$95K | – | 3936 |
|
|
2022
Q4 | $95K | Sell |
163,400
-1,435
| -0.9% | -$450 | ﹤0.01% | 3813 |
|
|
2022
Q3 | $52K | Buy |
164,835
+153,637
| +1,372% | +$60.3K | ﹤0.01% | 3893 |
|
|
2022
Q2 | $4K | Buy |
+11,198
| New | +$4.7K | ﹤0.01% | 3875 |
|
|
2022
Q1 | – | Sell |
-10,549
| Closed | -$24K | – | 3931 |
|
|
2021
Q4 | $24K | Sell |
10,549
-4,748
| -31% | -$12.9K | ﹤0.01% | 3922 |
|
|
2021
Q3 | $44K | Sell |
15,297
-39,580
| -72% | -$113K | ﹤0.01% | 3820 |
|
|
2021
Q2 | $208K | Buy |
54,877
+34,380
| +168% | +$116K | ﹤0.01% | 3742 |
|
|
2021
Q1 | $69K | Buy |
20,497
+3,018
| +17% | +$10.9K | ﹤0.01% | 3793 |
|
|
2020
Q4 | $49K | Buy |
17,479
+421
| +2% | +$1.23K | ﹤0.01% | 3724 |
|
|
2020
Q3 | $43K | Sell |
17,058
-116,707
| -87% | -$1.02M | ﹤0.01% | 3683 |
|
|
2020
Q2 | $1.82M | Buy |
133,765
+94,829
| +244% | +$981K | ﹤0.01% | 2658 |
|
|
2020
Q1 | $295K | Buy |
38,936
+1,260
| +3% | +$9.8K | ﹤0.01% | 3307 |
|
|
2019
Q4 | $238K | Buy |
37,676
+2,875
| +8% | +$13.7K | ﹤0.01% | 3535 |
|
|
2019
Q3 | $133K | Buy |
34,801
+5,845
| +20% | +$25K | ﹤0.01% | 3611 |
|
|
2019
Q2 | $140K | Sell |
28,956
-35,400
| -55% | -$201K | ﹤0.01% | 3634 |
|
|
2019
Q1 | $527K | Sell |
64,356
-143,734
| -69% | -$986K | ﹤0.01% | 3276 |
|
|
2018
Q4 | $1.15M | Buy |
208,090
+171,766
| +473% | +$1.34M | ﹤0.01% | 2889 |
|
|
2018
Q3 | $321K | Buy |
36,324
+16,740
| +85% | +$150K | ﹤0.01% | 3424 |
|
|
2018
Q2 | $196K | Sell |
19,584
-66,995
| -77% | -$671K | ﹤0.01% | 3493 |
|
|
2018
Q1 | $825K | Sell |
86,579
-81,627
| -49% | -$1.14M | ﹤0.01% | 3052 |
|
|
2017
Q4 | $2.5M | Buy |
168,206
+11,706
| +7% | +$194K | ﹤0.01% | 2552 |
|
|
2017
Q3 | $3.08M | Buy |
156,500
+71,845
| +85% | +$1.1M | ﹤0.01% | 2392 |
|
|
2017
Q2 | $1.22M | Buy |
+84,655
| New | +$1.07M | ﹤0.01% | 2856 |
|
|
2016
Q1 | – | Sell |
-186,524
| Closed | -$2.41M | – | 3750 |
|
|
2015
Q4 | $2.41M | Buy |
186,524
+13,190
| +8% | +$135K | ﹤0.01% | 2489 |
|
|
2015
Q3 | $1.67M | Buy |
+173,334
| New | +$1.59M | ﹤0.01% | 2713 |
|
Other funds holding AKBA
VCM
VPM
Ameriprise's AKBA Position: Q1 2026 in Review
Ameriprise reduced its Akebia Therapeutics (AKBA) stake by 5.5% in Q1 2026, selling an estimated $831 and leaving 10,391 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4036.
Ameriprise first reported a position in AKBA in Q3 2015 and has held it in 30 quarters since. The position peaked at $3.08M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Ameriprise held 10,391 shares of Akebia Therapeutics worth $14.4K as of Q1 2026.
- Ameriprise sold 605 Akebia Therapeutics shares in Q1 2026, an estimated $831.
- Akebia Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #4036 holding.
- Ameriprise first reported a position in Akebia Therapeutics in Q3 2015 and has held it in 30 quarters since.
- Ameriprise's Akebia Therapeutics position peaked at $3.08M in Q3 2017.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.